Johnson and johnson vaccine production11/28/2023 If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. These statements are based on current expectations of future events. The reader is cautioned not to rely on these forward-looking statements. This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for COVID-19. Learn more at Follow us at to Investors Concerning Forward-Looking Statements We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Learn more at Follow us at the Janssen Pharmaceutical CompaniesĪt Janssen, we're creating a future where disease is a thing of the past. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. ![]() Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. ![]() That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. There is currently no approved vaccine, treatment or cure for COVID-19.įor more information on Johnson & Johnson’s multi-pronged approach to combatting the pandemic, visit: About Johnson & JohnsonĪt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. The same technology was used to develop and manufacture the Company’s investigational Ebola vaccine and construct our RSV and HIV vaccine candidates which are in Phase 2 or Phase 3 clinical development stages.ĬOVID-19 belongs to a group of viruses called coronaviruses that attack the respiratory system. The COVID-19 vaccine program leverages Janssen’s proven AdVac ® and PER.C6 ® technologies that provide the ability to rapidly develop new vaccine candidates and upscale production of the optimal vaccine candidate. ![]() The additional global capacity will assist in the rapid production of a vaccine and enable the supply of more than one billion doses of a safe and effective vaccine to people around the world.įor more than 20 years, Johnson & Johnson has invested billions of dollars in antivirals and vaccine capabilities. Simultaneously, Johnson & Johnson is also aiming to rapidly scale up vaccine manufacturing capabilities globally, including increasing capacity in countries outside the U.S. Johnson & Johnson will begin production at risk and is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use. The Company has already begun preparations for clinical vaccine production at its facility in Leiden, the Netherlands, with the aim of initiating Phase 1 human clinical studies of its vaccine candidate in September 2020. ![]() Emergent will provide drug substance manufacturing services with its molecule-to-market CDMO offering, beginning in 2020, and will also reserve operations capacity to potentially support commercial manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate leveraging Janssen’s proven AdVac® and PER.C6 ® technologies beginning in 2021. Under the terms of this manufacturing agreement, Johnson & Johnson is investing to expand drug substance capacity related to the vaccine candidate. Our collaboration with Emergent is proof that we are moving quickly to deliver on that promise.” Johnson & Johnson has committed to rapidly produce and supply more than one billion doses of a safe and effective vaccine globally. Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, “We have set a high bar. This is the first in a series of prospective global collaboration agreements designed to accelerate manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate, and further the Company’s goal to supply more than one billion doses of the vaccine globally. to support the manufacturing of its lead investigational COVID-19 vaccine candidate. NEW BRUNSWICK, N.J., ApJohnson & Johnson (the Company) (NYSE: JNJ) today announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |